18F-FDG hPET/CT显像在非小细胞肺癌临床分期中的应用

目的探讨^18F-脱氧葡萄糖hPET/CT（^18F-FDG hPET/CT）显像在非小细胞肺癌（NSCLC）临床分期中的应用价值。方法72例NSCLC患者于放疗前行^18F-FDG hPET/CT显像检查，进行FDG分期，并将FDG分期和CT分期结果进行比较分析。结果^18F-FDG hPET/CT显像使27例NSCLC患者分期改变，其中分期升级20例，分期降级7例。14例分期升级者^18F-FDG hPET/CT显像检查发现了远处转移灶，其治疗方案由根治性治疗改为姑息性治疗。FDG显像较CT多发现了47个转移淋巴结，并对其进行了放疗；多发现了26个远处转移灶，并对其进行了姑息性放疗。结论^18F-FDG hPET/CT显像改变了37．5％（27／72）NSCLC患者的临床分期，影响了其治疗策略及放疗计划，使得治疗更加合理。

Application of 18F-FDG hybrid PET/CT imaging in clinical staging of non-small cell lung cancer

Objective To investigate the application of ~(18)F-fluorodeoxyglucose hybrid PET/CT (~(18)F-FDG hPET/CT) imaging in clinical staging of non-small cell lung cancer (NSCLC). Methods Seventy two consecutive patients with NSCLC undergoing ~(18)F-FDG hPET/CT before radiotherapy were analyzed. The results were compared with previous CT scan and conventional clinical staging. The patients were followed-up for at least 6 months. Results Among the 72 patients, the staging grade was changed in 27 patients due to the result of ~(18)F-FDG hPET/CT in whom with 20 patients having their grade raised and 7 lowered. Radical treatment was changed to palliative treatment in view of a raise of staging grade. Because of distant metastasis was detected by ~(18)F-FDG hPET/CT imaging, 14 patients received palliative treatment. Compared with CT, 47 more lymph nodes and 26 distant metastases were found with ~(18)F-FDG hPET/CT imaging, and the patients in question received radiotherapy and palliative treatment accordingly. Conclusion ~(18)F-FDG hPET/CT imaging, by changing the clinical staging in 37.5% (27/72) NSCLC patients, has impact on treatment strategy and treatment planning of radiotherapy in NSCLC patients. Patients were frequently spared unnecessary treatment, and management was more appropriately targeted.